Diagnosis of Malignant Ocular Tumours with Radioactive Phosphorus (32P)

2015 ◽  
pp. 168-170
Author(s):  
R. A. van Dijk ◽  
J. A. Oosterhuis
Keyword(s):  
Radioactive Phosphorus ◽  
Ocular Tumours

Diagnosis of Malignant Ocular Tumours with Radioactive Phosphorus (32P)

1976 ◽  
Vol 173 (3-4) ◽  
pp. 168-170
Author(s):  
R.A. van Dijk ◽  
J.A. Oosterhuis
Keyword(s):  
Radioactive Phosphorus ◽  
Ocular Tumours

DETERMINATION OF THYROTROPHIN BY MEANS OF RADIOACTIVE PHOSPHORUS

1949 ◽  
Vol 3 (4) ◽  
pp. 331-341 ◽  
Author(s):  
ULF BORELL ◽  
HJALMAR HOLMGREN
Keyword(s):  
Radioactive Phosphorus

scholarly journals RADIOACTIVE PHOSPHORUS AS AN INDICATOR OF PHOSPHOLIPID METABOLISM

1938 ◽  
Vol 126 (2) ◽  
pp. 493-500 ◽  
Author(s):  
G.W. Changus ◽  
I.L. Chaikoff ◽  
S. Ruben
Keyword(s):  
Phospholipid Metabolism ◽  
Radioactive Phosphorus

Combined chemotherapy and EUS-guided intra-tumoral 32-P implantation for locally advanced pancreatic ductal adenocarcinoma: a pilot study

Endoscopy ◽  
2021 ◽  
Author(s):  
Jeevinesh Naidu ◽  
Dylan Bartholomeusz ◽  
Joshua Zobel ◽  
Romina Safaeian ◽  
William Hsieh ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Adelaide Hospital ◽  
Response To Treatment ◽  
Ductal Adenocarcinoma ◽  
Resection Margins ◽  
R0 Resection ◽  
Royal Adelaide Hospital ◽  
Combined Chemotherapy ◽  
Radioactive Phosphorus ◽  
18Fdg Pet

Aim: This study evaluated clinical outcomes of combined chemotherapy and Endoscopic Ultrasound (EUS) guided intra-tumoral radioactive phosphorus-32 (32P OncoSil) implantation in locally advanced pancreatic adenocarcinoma (LAPC). Methods: Consecutive patients with a new histological diagnosis of LAPC were recruited over 20 months. Baseline CT and 18FDG PET-CT were performed and repeated after 12 weeks to assess response to treatment. Following 2 cycles of conventional chemotherapy, patients underwent EUS-guided 32P OncoSil implantation followed by a further six cycles of chemotherapy. Results: Twelve patients with LAPC (8M:4F; median age 69 years, IQR 61.5-73.3) completed the treatment. Technical success was 100% and no procedural complications were reported. At 12 weeks, there was a median reduction of 8.2cm3 (95% CI 4.95-10.85; p=0.003) in tumour volume, with minimal or no 18FDG uptake in 9 (75%) patients. Tumour downstaging was achieved in 6 (50%) patients, leading to successful resection in 5 (42%) patients, of which 4 patients (80%) had clear (R0) resection margins. Conclusions: EUS guided 32P OncoSil implantation is feasible and well tolerated and was associated with a 42% rate of surgical resection in our cohort. However, further evaluation in a larger randomized multicenter trial is warranted. (32P funded by OncoSil Medical Ltd, equipment and staff funded by the Royal Adelaide Hospital, ClinicalTrials.gov number, NCT03003078).

Determination of circulating red blood cell volume with radioactive phosphorus

1949 ◽  
Vol 7 (2) ◽  
pp. 259
Author(s):  
R.T. Nieset ◽  
Blanche Porter ◽  
W.S. Trautman ◽  
Ralph M. Bell ◽  
William Parson ◽  
...  
Keyword(s):  
Blood Cell ◽  
Cell Volume ◽  
Red Blood Cell ◽  
Radioactive Phosphorus
Sign in / Sign up

Export Citation Format

Share Document